Cellzome

Cellzome is a leading pharmaceutical manufacturing company dedicated to identifying and developing a new generation of kinase-targeted drugs for treating inflammatory diseases. Cellzome's innovative approach is driven by Kinobeads™ technology, a proprietary method for screening and profiling kinases in relevant cells and tissues. This advanced technology enables Cellzome to create highly selective kinase inhibitors that target key inflammatory mediators in immune receptor signaling and chemotaxis, including PI3Kγ and Zap-70.

Located at Chesterford Research Park, Little Chesterford, Cambridge, CB10 1XL, GB, and Meyerhofstrasse 1, Heidelberg, 69117, DE, Cellzome is committed to advancing drug discovery and development. With a focus on inflammation and proteomics, Cellzome is dedicated to improving patient outcomes through its innovative therapeutic pipeline. The company's focus remains steadfast on discovering and developing novel treatments that address critical unmet needs in inflammatory diseases.

Cellzome is actively expanding its reach and impact within the pharmaceutical industry. We invite the management team to create a customized and exclusive company showcase and product listing on our platform to further enhance your commercial development.